Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared With Rituximab in Subjects With CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL)
Conditions
Interventions
ABP 798
Rituximab
Locations
98
United States
Research Site
Encinitas, California, United States
Research Site
Mount Sterling, Kentucky, United States
Research Site
Billings, Montana, United States
Research Site
Zanesville, Ohio, United States
Research Site
Roanoke, Virginia, United States
Research Site
Gosford, New South Wales, Australia
Start Date
May 25, 2016
Primary Completion Date
June 28, 2019
Completion Date
June 28, 2019
Last Updated
September 10, 2022
NCT06510361
NCT05442515
NCT07162181
NCT06528301
NCT05824585
NCT04460235
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions